Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan

Norio Sugawara,1,2 Shuhei Kudo,2 Masamichi Ishioka,3 Yasushi Sato,2,4 Kazutoshi Kubo,3 Norio Yasui-Furukori2 1Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry, Kodaira, Japan; 2Department of Neuropsychiatry, Hirosaki University School of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sugawara N, Kudo S, Ishioka M, Sato Y, Kubo K, Yasui-Furukori N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	adherence long-acting injectable antipsychotics schizophrenia attitude Japanese Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/3eca569023e1450b88d236b1d948ff65
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3eca569023e1450b88d236b1d948ff65
record_format	dspace
spelling	oai:doaj.org-article:3eca569023e1450b88d236b1d948ff652021-12-02T04:57:00ZAttitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan1178-2021https://doaj.org/article/3eca569023e1450b88d236b1d948ff652019-01-01T00:00:00Zhttps://www.dovepress.com/attitudes-toward-long-acting-injectable-antipsychotics-among-patients--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Norio Sugawara,1,2 Shuhei Kudo,2 Masamichi Ishioka,3 Yasushi Sato,2,4 Kazutoshi Kubo,3 Norio Yasui-Furukori2 1Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry, Kodaira, Japan; 2Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki, Japan; 3Department of Psychiatry, Hirosaki-Aiseikai Hospital, Hirosaki, Japan; 4Department of Psychiatry, Seihoku-Chuoh Hospital, Goshogawara, Japan Background: Long-acting injectable antipsychotics (LAIs) are regarded as an important alternative to oral medication for patients with schizophrenia. However, LAIs remain underutilized in clinical practice.Aims: The aims of this investigation were to 1) obtain information on patients’ attitudes toward LAIs and 2) assess factors associated with patients’ acceptance of LAIs, and 3) identify predictors of the discrepancy between patients and referring psychiatrists’ opinions regarding the appropriateness for LAIs.Methods: Anonymized data were collected from a questionnaire distributed to 159 patients with schizophrenia and their referring psychiatrists at three psychiatric hospitals between February 2014 and July 2014. The patients completed an original questionnaire developed to evaluate their attitudes regarding LAIs. Regarding the appropriateness of LAI prescription, patients and their referring psychiatrists were asked to rate, on a 5-point scale, how appropriate they felt the depot prescription was for the patients. The participants also answered instruments to assess symptom severity, antipsychotic-induced extrapyramidal symptoms, functions, quality of life, and self-esteem levels.Results: Patients currently on LAIs have favorable attitudes toward LAIs with respect to side effects, relapse prevention, efficacy, pain, and cost. Expectation of relapse prevention was significantly associated with patients’ acceptance of LAIs (answering that those drugs are appropriate for their own treatment). In addition, the discrepancy between the patients’ and referring psychiatrists’ opinions regarding the appropriateness of LAI treatment was significantly associated with symptom severity, expectation of relapse prevention, belief that LAIs are painful, and belief that LAIs offer a reduced range of antipsychotic choices.Conclusion: Attitudes toward LAIs need to be considered when deciding whether to prescribe this formulation. Access to information on LAIs, including their benefit in relapse prevention, might enhance the acceptance and use of this formulation among patients with schizophrenia. Keywords: adherence, long-acting injectable antipsychotics, schizophrenia, attitude, JapaneseSugawara NKudo SIshioka MSato YKubo KYasui-Furukori NDove Medical Pressarticleadherencelong-acting injectable antipsychoticsschizophreniaattitudeJapaneseNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 205-211 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	adherence long-acting injectable antipsychotics schizophrenia attitude Japanese Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	adherence long-acting injectable antipsychotics schizophrenia attitude Japanese Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Sugawara N Kudo S Ishioka M Sato Y Kubo K Yasui-Furukori N Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
description	Norio Sugawara,1,2 Shuhei Kudo,2 Masamichi Ishioka,3 Yasushi Sato,2,4 Kazutoshi Kubo,3 Norio Yasui-Furukori2 1Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry, Kodaira, Japan; 2Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki, Japan; 3Department of Psychiatry, Hirosaki-Aiseikai Hospital, Hirosaki, Japan; 4Department of Psychiatry, Seihoku-Chuoh Hospital, Goshogawara, Japan Background: Long-acting injectable antipsychotics (LAIs) are regarded as an important alternative to oral medication for patients with schizophrenia. However, LAIs remain underutilized in clinical practice.Aims: The aims of this investigation were to 1) obtain information on patients’ attitudes toward LAIs and 2) assess factors associated with patients’ acceptance of LAIs, and 3) identify predictors of the discrepancy between patients and referring psychiatrists’ opinions regarding the appropriateness for LAIs.Methods: Anonymized data were collected from a questionnaire distributed to 159 patients with schizophrenia and their referring psychiatrists at three psychiatric hospitals between February 2014 and July 2014. The patients completed an original questionnaire developed to evaluate their attitudes regarding LAIs. Regarding the appropriateness of LAI prescription, patients and their referring psychiatrists were asked to rate, on a 5-point scale, how appropriate they felt the depot prescription was for the patients. The participants also answered instruments to assess symptom severity, antipsychotic-induced extrapyramidal symptoms, functions, quality of life, and self-esteem levels.Results: Patients currently on LAIs have favorable attitudes toward LAIs with respect to side effects, relapse prevention, efficacy, pain, and cost. Expectation of relapse prevention was significantly associated with patients’ acceptance of LAIs (answering that those drugs are appropriate for their own treatment). In addition, the discrepancy between the patients’ and referring psychiatrists’ opinions regarding the appropriateness of LAI treatment was significantly associated with symptom severity, expectation of relapse prevention, belief that LAIs are painful, and belief that LAIs offer a reduced range of antipsychotic choices.Conclusion: Attitudes toward LAIs need to be considered when deciding whether to prescribe this formulation. Access to information on LAIs, including their benefit in relapse prevention, might enhance the acceptance and use of this formulation among patients with schizophrenia. Keywords: adherence, long-acting injectable antipsychotics, schizophrenia, attitude, Japanese
format	article
author	Sugawara N Kudo S Ishioka M Sato Y Kubo K Yasui-Furukori N
author_facet	Sugawara N Kudo S Ishioka M Sato Y Kubo K Yasui-Furukori N
author_sort	Sugawara N
title	Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
title_short	Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
title_full	Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
title_fullStr	Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
title_full_unstemmed	Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
title_sort	attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in japan
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/3eca569023e1450b88d236b1d948ff65
work_keys_str_mv	AT sugawaran attitudestowardlongactinginjectableantipsychoticsamongpatientswithschizophreniainjapan AT kudos attitudestowardlongactinginjectableantipsychoticsamongpatientswithschizophreniainjapan AT ishiokam attitudestowardlongactinginjectableantipsychoticsamongpatientswithschizophreniainjapan AT satoy attitudestowardlongactinginjectableantipsychoticsamongpatientswithschizophreniainjapan AT kubok attitudestowardlongactinginjectableantipsychoticsamongpatientswithschizophreniainjapan AT yasuifurukorin attitudestowardlongactinginjectableantipsychoticsamongpatientswithschizophreniainjapan
_version_	1718400942667202560

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan

Ejemplares similares